Johnson & Johnson

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Published: December 6, 2025 – For information only, not investment advice. Johnson & Johnson stock (NYSE: JNJ) is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings

6 December 2025

Johnson & Johnson (JNJ) Stock: Price, Latest News, Analyst Forecasts and Dividend Outlook – December 5, 2025

Johnson & Johnson (NYSE: JNJ) stock has surged in 2025 and is now trading close to record highs, while Wall Street remains broadly positive but increasingly divided on just how much upside is left from here. As of December 5,

5 December 2025

Analyst Forecasts · Dividends · Financial News · Investing · NYSE:JNJ · Stocks

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

As of December 2, 2025, Johnson & Johnson (NYSE: JNJ) is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its

2 December 2025

Business News · Healthcare Industry · Investing · NYSE:JNJ · Pharmaceuticals · Stock Market

Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength – December 1, 2025

As of December 1, 2025. This article is for information only and is not investment advice. JNJ stock today: riding near record highs after a huge 2025 rally Johnson & Johnson (NYSE: JNJ) stock is trading close to its 52‑week

1 December 2025

Cancer Research · Dividend Stocks · Investment News · NYSE:JNJ · Pharma Industry · Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: What Investors Should Know Before the December 1, 2025 Market Open

Johnson & Johnson (NYSE: JNJ) heads into the new trading week sitting just under all‑time highs, after a powerful rally that’s pushed the healthcare giant toward a $500 billion market value. FinancialContent+1 With U.S. markets reopening on Monday, December 1,

30 November 2025

Company Analysis · Financial News · Investing Tips · Market Trends · NYSE:JNJ · Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: Is the $500 Billion Healthcare Giant Still a Buy in 2025?

Updated: November 30, 2025 Johnson & Johnson stock has quietly turned into one of 2025’s big winners. After years of trading like a sleepy defensive name, JNJ has gone on an 11‑ to 13‑day winning streak, pushed its market capitalization

30 November 2025

Company Analysis · Financial News · Healthcare Stocks · Investing · NYSE:JNJ · Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: Today’s News, Earnings, Dividend and Talc Risks – November 29, 2025

On November 29, 2025, Johnson & Johnson (NYSE: JNJ) sits close to record territory after a powerful year-long rally, with Wall Street increasingly treating the healthcare giant as both a growth and defensive name at the same time. The stock

29 November 2025

Dividends · Earnings Reports · JNJ · Legal Risks · NYSE:JNJ · Stock Market

Johnson & Johnson Stock (JNJ) Near Record Highs: Earnings Momentum, Spin‑Off Plans and Talc Risks in 2025

Published: November 29, 2025 – This article is for information only and is not financial advice. JNJ stock today: a mega‑cap back in the spotlight Johnson & Johnson stock (NYSE: JNJ) is ending November 2025 right up against its all‑time

29 November 2025

Earnings Reports · Healthcare Sector · Investment Strategies · NYSE:JNJ · Risk Analysis · Stock Market

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Updated: November 28, 2025 Johnson & Johnson (JNJ) is closing out 2025 as one of the standout “defensive” winners in the U.S. market. The stock is trading just below a fresh 52‑week high around $205–$208 per share, giving the healthcare

28 November 2025

Corporate Strategy · Investment Analysis · Legal Risks · Pharmaceuticals · Stock Market

Johnson & Johnson (JNJ) Stock Today – November 26, 2025: 12‑Day Rally Pushes Shares Toward $500 Billion Valuation

Johnson & Johnson (NYSE: JNJ) is quietly turning into one of 2025’s standout mega‑cap stories. By this afternoon on Wednesday, November 26, J&J shares were trading around $207 per share, up modestly on the day and hovering near their all‑time

26 November 2025

Company Analysis · Financial News · Investments · Market Trends · NYSE:JNJ · Stock Market

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on

17 November 2025

Biotech Industry · Mergers & Acquisitions · NASDAQ:CDTX · NYSE:JNJ · NYSE:MRK · NYSE:PFE · Oncology · Patent News · Pharmaceuticals

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Johnson & Johnson Stock Primed for Rally? Premarket Insights for Nov 3, 2025

Earnings & Guidance Lift Hopes Johnson & Johnson’s Q3 report and guidance boost have underpinned recent optimism. Excluding currency effects, total sales rose 6.8% to $23.99B, with key drugs like Darzalex ($3.67B) and its autoimmune blockbusters driving growth ts2.tech reuters.com.

2 November 2025

Financial News · Investing · Johnson & Johnson · Premarket Analysis · Stock Market